Global and Regional Autoimmune Treatment
Global and Regional Autoimmune Treatment

Autoimmune Treatment Comprehensive Study by Type (Drugs, Diagnostic Equipment, Therapeutic and Monitoring Equipment, Other Products), Application (Childhood, Adult), Disease Type (Localized, Systemic), Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, Others), Sales Channel (Hospital Pharmacy,, Drug Store & Retail Pharmacy, Online Store), Diagnosis (ELISA, Dot Blot, Agglutination, Others) Players and Region - Global Market Outlook to 2024

Autoimmune Treatment Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024 | CAGR: 4.1%  

Jul 2019 Edition 206 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Autoimmune Treatment Market Overview:
Autoimmune Treatment is required in those conditions when the body immune system destroy its own body tissue. Autoimmune Treatment market is expected to mark significant growth over forecasted period owing to increasing prevalence of autoimmune diseases, providing high disposable income with the population and technological advancement. There has been significant rise in number of people suffering from autoimmune disease with figure stood up to 23.5 million in United States alone in 2018, so the future for Autoimmune Treatment looks promising. This result in rising popularity and wide availability of advanced therapeutics, increasing demand of pipeline drugs and escalating need for improved healthcare infrastructure of Autoimmune Treatment may trigger demand and help in industry expansion. According to AMA, the Global Autoimmune Treatment market is expected to see growth rate of 4.1% and may see market size of USD142.8 Million by 2024.

Market Drivers
  • Prevalence of Multiple Sclerosis Disease Boost the Autoimmune Treatment Market.
  • Customer Awareness Fuelled Up the Autoimmune Treatment Market.

Market Trend
  • Collaboration and Tie Up Of Leading Players
  • Rapidly improving healthcare infrastructure boost the market

Restraints
  • Complicated Diseases and Limited Drugs Hampers The Market.
  • High Cost of Oral Drugs Associated with Autoimmune Treatment Market.

Opportunities
  • Presence of Government Initiatives Leads to Grow the Autoimmune Treatment Market.
  • Growth in R&D Activities Leads to Develop the Autoimmune Treatment Market

Challenges
  • Lacks of Skilled Professional in Diagnosis Process will Challenge the Market.
  • Sophisticated Lab Automation Hampers The Global Market.


Competitive Landscape:

Some of the key players profiled in the report are Abbott Laboratories (United States), Glaxo Smithkline Plc (United Kingdom), Mitsubishi Tanabe Pharma Corp (Japan), Lupin (India), Johnson & Johnson (United States), Pfizer (United States), Novartis (United States), Roche (Switzerland), Eli Lilly & Co. (United States) and Boehringer Ingelheim Gmbh (Germany). Additionally, following companies can also be profiled that are part of our coverage like Bayer-Schering Pharmaceuticals (Germany), Amgen (United States), Genentech, Inc. (United States), Bristol-Myers Squibb Co. (United States) and Biocryst Pharmaceuticals Inc. (United States). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Autoimmune Treatment market by 2024. Considering Market by Disease Type, the sub-segment i.e. Localized will boost the Autoimmune Treatment market. Considering Market by Indication, the sub-segment i.e. Rheumatic Disease will boost the Autoimmune Treatment market. Considering Market by Sales Channel, the sub-segment i.e. Hospital Pharmacy, will boost the Autoimmune Treatment market. Considering Market by Diagnosis, the sub-segment i.e. ELISA will boost the Autoimmune Treatment market.

Market Highlights:
“According to government of India, its provide Essential Commodities Act, 1955,where Biofertiliser means the product containing carrier based (solid or liquid) living microorganisms which are agriculturally useful in terms of nitrogen fixation, phosphorus solubilisation or nutrient mobilization, to increase the productivity of the soil.”

In March 2019, Eli lily and ImmuNext partnered to develop a preclinical novel potential target for autoimmune disease treatment which is beneficial in providing new medicines for patients suffering with autoimmune diseases.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Autoimmune Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Autoimmune Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Autoimmune Treatment Manufacturers, Autoimmune Treatment Traders, End-Use Market Participants of Different Segments of Autoimmune Treatment, Government and Research Organizations, R&D Institutions and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Drugs
  • Diagnostic Equipment
  • Therapeutic and Monitoring Equipment
  • Other Products
By Application
  • Childhood
  • Adult
By Disease Type
  • Localized
  • Systemic

By Indication
  • Rheumatic Disease
  • Type 1 Diabetes
  • Multiple Sclerosis
  • Inflammatory Bowel Disease
  • Others

By Sales Channel
  • Hospital Pharmacy,
  • Drug Store & Retail Pharmacy
  • Online Store

By Diagnosis
  • ELISA
  • Dot Blot
  • Agglutination
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Multiple Sclerosis Disease Boost the Autoimmune Treatment Market.
      • 3.2.2. Customer Awareness Fuelled Up the Autoimmune Treatment Market.
    • 3.3. Market Challenges
      • 3.3.1. Lacks of Skilled Professional in Diagnosis Process will Challenge the Market.
      • 3.3.2. Sophisticated Lab Automation Hampers The Global Market.
    • 3.4. Market Trends
      • 3.4.1. Collaboration and Tie Up Of Leading Players
      • 3.4.2. Rapidly improving healthcare infrastructure boost the market
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Autoimmune Treatment, by Type, Application, Disease Type, Indication, Sales Channel, Diagnosis and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Autoimmune Treatment (Value)
      • 5.2.1. Global Autoimmune Treatment by: Type (Value)
        • 5.2.1.1. Drugs
        • 5.2.1.2. Diagnostic Equipment
        • 5.2.1.3. Therapeutic and Monitoring Equipment
        • 5.2.1.4. Other Products
      • 5.2.2. Global Autoimmune Treatment by: Application (Value)
        • 5.2.2.1. Childhood
        • 5.2.2.2. Adult
      • 5.2.3. Global Autoimmune Treatment by: Disease Type (Value)
        • 5.2.3.1. Localized
        • 5.2.3.2. Systemic
      • 5.2.4. Global Autoimmune Treatment by: Indication (Value)
        • 5.2.4.1. Rheumatic Disease
        • 5.2.4.2. Type 1 Diabetes
        • 5.2.4.3. Multiple Sclerosis
        • 5.2.4.4. Inflammatory Bowel Disease
        • 5.2.4.5. Others
      • 5.2.5. Global Autoimmune Treatment by: Sales Channel (Value)
        • 5.2.5.1. Hospital Pharmacy,
        • 5.2.5.2. Drug Store & Retail Pharmacy
        • 5.2.5.3. Online Store
      • 5.2.6. Global Autoimmune Treatment by: Diagnosis (Value)
        • 5.2.6.1. ELISA
        • 5.2.6.2. Dot Blot
        • 5.2.6.3. Agglutination
        • 5.2.6.4. Others
      • 5.2.7. Global Autoimmune Treatment Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Autoimmune Treatment (Price)
      • 5.3.1. Global Autoimmune Treatment by: Type (Price)
  • 6. Autoimmune Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Glaxo Smithkline Plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mitsubishi Tanabe Pharma Corp (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lupin (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Roche (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly & Co. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Boehringer Ingelheim Gmbh (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Autoimmune Treatment Sale, by Type, Application, Disease Type, Indication, Sales Channel, Diagnosis and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Autoimmune Treatment (Value)
      • 7.2.1. Global Autoimmune Treatment by: Type (Value)
        • 7.2.1.1. Drugs
        • 7.2.1.2. Diagnostic Equipment
        • 7.2.1.3. Therapeutic and Monitoring Equipment
        • 7.2.1.4. Other Products
      • 7.2.2. Global Autoimmune Treatment by: Application (Value)
        • 7.2.2.1. Childhood
        • 7.2.2.2. Adult
      • 7.2.3. Global Autoimmune Treatment by: Disease Type (Value)
        • 7.2.3.1. Localized
        • 7.2.3.2. Systemic
      • 7.2.4. Global Autoimmune Treatment by: Indication (Value)
        • 7.2.4.1. Rheumatic Disease
        • 7.2.4.2. Type 1 Diabetes
        • 7.2.4.3. Multiple Sclerosis
        • 7.2.4.4. Inflammatory Bowel Disease
        • 7.2.4.5. Others
      • 7.2.5. Global Autoimmune Treatment by: Sales Channel (Value)
        • 7.2.5.1. Hospital Pharmacy,
        • 7.2.5.2. Drug Store & Retail Pharmacy
        • 7.2.5.3. Online Store
      • 7.2.6. Global Autoimmune Treatment by: Diagnosis (Value)
        • 7.2.6.1. ELISA
        • 7.2.6.2. Dot Blot
        • 7.2.6.3. Agglutination
        • 7.2.6.4. Others
      • 7.2.7. Global Autoimmune Treatment Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Autoimmune Treatment (Price)
      • 7.3.1. Global Autoimmune Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Autoimmune Treatment: by Type(USD Million)
  • Table 2. Autoimmune Treatment Drugs , by Region USD Million (2013-2018)
  • Table 3. Autoimmune Treatment Diagnostic Equipment , by Region USD Million (2013-2018)
  • Table 4. Autoimmune Treatment Therapeutic and Monitoring Equipment , by Region USD Million (2013-2018)
  • Table 5. Autoimmune Treatment Other Products , by Region USD Million (2013-2018)
  • Table 6. Autoimmune Treatment: by Application(USD Million)
  • Table 7. Autoimmune Treatment Childhood , by Region USD Million (2013-2018)
  • Table 8. Autoimmune Treatment Adult , by Region USD Million (2013-2018)
  • Table 9. Autoimmune Treatment: by Disease Type(USD Million)
  • Table 10. Autoimmune Treatment Localized , by Region USD Million (2013-2018)
  • Table 11. Autoimmune Treatment Systemic , by Region USD Million (2013-2018)
  • Table 12. Autoimmune Treatment: by Indication(USD Million)
  • Table 13. Autoimmune Treatment Rheumatic Disease , by Region USD Million (2013-2018)
  • Table 14. Autoimmune Treatment Type 1 Diabetes , by Region USD Million (2013-2018)
  • Table 15. Autoimmune Treatment Multiple Sclerosis , by Region USD Million (2013-2018)
  • Table 16. Autoimmune Treatment Inflammatory Bowel Disease , by Region USD Million (2013-2018)
  • Table 17. Autoimmune Treatment Others , by Region USD Million (2013-2018)
  • Table 18. Autoimmune Treatment: by Sales Channel(USD Million)
  • Table 19. Autoimmune Treatment Hospital Pharmacy, , by Region USD Million (2013-2018)
  • Table 20. Autoimmune Treatment Drug Store & Retail Pharmacy , by Region USD Million (2013-2018)
  • Table 21. Autoimmune Treatment Online Store , by Region USD Million (2013-2018)
  • Table 22. Autoimmune Treatment: by Diagnosis(USD Million)
  • Table 23. Autoimmune Treatment ELISA , by Region USD Million (2013-2018)
  • Table 24. Autoimmune Treatment Dot Blot , by Region USD Million (2013-2018)
  • Table 25. Autoimmune Treatment Agglutination , by Region USD Million (2013-2018)
  • Table 26. Autoimmune Treatment Others , by Region USD Million (2013-2018)
  • Table 27. South America Autoimmune Treatment, by Country USD Million (2013-2018)
  • Table 28. South America Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 29. South America Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 30. South America Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 31. South America Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 32. South America Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 33. South America Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 34. Brazil Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 35. Brazil Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 36. Brazil Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 37. Brazil Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 38. Brazil Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 39. Brazil Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 40. Argentina Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 41. Argentina Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 42. Argentina Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 43. Argentina Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 44. Argentina Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 45. Argentina Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 46. Rest of South America Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 47. Rest of South America Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 48. Rest of South America Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 49. Rest of South America Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 50. Rest of South America Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 51. Rest of South America Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 52. Asia Pacific Autoimmune Treatment, by Country USD Million (2013-2018)
  • Table 53. Asia Pacific Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 54. Asia Pacific Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 55. Asia Pacific Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 56. Asia Pacific Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 57. Asia Pacific Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 58. Asia Pacific Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 59. China Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 60. China Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 61. China Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 62. China Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 63. China Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 64. China Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 65. Japan Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 66. Japan Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 67. Japan Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 68. Japan Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 69. Japan Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 70. Japan Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 71. India Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 72. India Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 73. India Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 74. India Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 75. India Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 76. India Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 77. South Korea Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 78. South Korea Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 79. South Korea Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 80. South Korea Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 81. South Korea Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 82. South Korea Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 83. Taiwan Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 84. Taiwan Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 85. Taiwan Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 86. Taiwan Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 87. Taiwan Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 88. Taiwan Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 89. Australia Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 90. Australia Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 91. Australia Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 92. Australia Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 93. Australia Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 94. Australia Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 95. Rest of Asia-Pacific Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 96. Rest of Asia-Pacific Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 97. Rest of Asia-Pacific Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 98. Rest of Asia-Pacific Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 99. Rest of Asia-Pacific Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 100. Rest of Asia-Pacific Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 101. Europe Autoimmune Treatment, by Country USD Million (2013-2018)
  • Table 102. Europe Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 103. Europe Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 104. Europe Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 105. Europe Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 106. Europe Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 107. Europe Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 108. Germany Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 109. Germany Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 110. Germany Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 111. Germany Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 112. Germany Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 113. Germany Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 114. France Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 115. France Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 116. France Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 117. France Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 118. France Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 119. France Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 120. Italy Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 121. Italy Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 122. Italy Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 123. Italy Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 124. Italy Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 125. Italy Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 126. United Kingdom Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 127. United Kingdom Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 128. United Kingdom Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 129. United Kingdom Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 130. United Kingdom Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 131. United Kingdom Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 132. Netherlands Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 133. Netherlands Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 134. Netherlands Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 135. Netherlands Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 136. Netherlands Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 137. Netherlands Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 138. Rest of Europe Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 139. Rest of Europe Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 140. Rest of Europe Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 141. Rest of Europe Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 142. Rest of Europe Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 143. Rest of Europe Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 144. MEA Autoimmune Treatment, by Country USD Million (2013-2018)
  • Table 145. MEA Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 146. MEA Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 147. MEA Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 148. MEA Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 149. MEA Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 150. MEA Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 151. Middle East Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 152. Middle East Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 153. Middle East Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 154. Middle East Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 155. Middle East Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 156. Middle East Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 157. Africa Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 158. Africa Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 159. Africa Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 160. Africa Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 161. Africa Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 162. Africa Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 163. North America Autoimmune Treatment, by Country USD Million (2013-2018)
  • Table 164. North America Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 165. North America Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 166. North America Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 167. North America Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 168. North America Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 169. North America Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 170. United States Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 171. United States Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 172. United States Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 173. United States Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 174. United States Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 175. United States Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 176. Canada Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 177. Canada Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 178. Canada Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 179. Canada Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 180. Canada Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 181. Canada Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 182. Mexico Autoimmune Treatment, by Type USD Million (2013-2018)
  • Table 183. Mexico Autoimmune Treatment, by Application USD Million (2013-2018)
  • Table 184. Mexico Autoimmune Treatment, by Disease Type USD Million (2013-2018)
  • Table 185. Mexico Autoimmune Treatment, by Indication USD Million (2013-2018)
  • Table 186. Mexico Autoimmune Treatment, by Sales Channel USD Million (2013-2018)
  • Table 187. Mexico Autoimmune Treatment, by Diagnosis USD Million (2013-2018)
  • Table 188. Autoimmune Treatment: by Type(USD/Units)
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Autoimmune Treatment: by Type(USD Million)
  • Table 200. Autoimmune Treatment Drugs , by Region USD Million (2019-2024)
  • Table 201. Autoimmune Treatment Diagnostic Equipment , by Region USD Million (2019-2024)
  • Table 202. Autoimmune Treatment Therapeutic and Monitoring Equipment , by Region USD Million (2019-2024)
  • Table 203. Autoimmune Treatment Other Products , by Region USD Million (2019-2024)
  • Table 204. Autoimmune Treatment: by Application(USD Million)
  • Table 205. Autoimmune Treatment Childhood , by Region USD Million (2019-2024)
  • Table 206. Autoimmune Treatment Adult , by Region USD Million (2019-2024)
  • Table 207. Autoimmune Treatment: by Disease Type(USD Million)
  • Table 208. Autoimmune Treatment Localized , by Region USD Million (2019-2024)
  • Table 209. Autoimmune Treatment Systemic , by Region USD Million (2019-2024)
  • Table 210. Autoimmune Treatment: by Indication(USD Million)
  • Table 211. Autoimmune Treatment Rheumatic Disease , by Region USD Million (2019-2024)
  • Table 212. Autoimmune Treatment Type 1 Diabetes , by Region USD Million (2019-2024)
  • Table 213. Autoimmune Treatment Multiple Sclerosis , by Region USD Million (2019-2024)
  • Table 214. Autoimmune Treatment Inflammatory Bowel Disease , by Region USD Million (2019-2024)
  • Table 215. Autoimmune Treatment Others , by Region USD Million (2019-2024)
  • Table 216. Autoimmune Treatment: by Sales Channel(USD Million)
  • Table 217. Autoimmune Treatment Hospital Pharmacy, , by Region USD Million (2019-2024)
  • Table 218. Autoimmune Treatment Drug Store & Retail Pharmacy , by Region USD Million (2019-2024)
  • Table 219. Autoimmune Treatment Online Store , by Region USD Million (2019-2024)
  • Table 220. Autoimmune Treatment: by Diagnosis(USD Million)
  • Table 221. Autoimmune Treatment ELISA , by Region USD Million (2019-2024)
  • Table 222. Autoimmune Treatment Dot Blot , by Region USD Million (2019-2024)
  • Table 223. Autoimmune Treatment Agglutination , by Region USD Million (2019-2024)
  • Table 224. Autoimmune Treatment Others , by Region USD Million (2019-2024)
  • Table 225. South America Autoimmune Treatment, by Country USD Million (2019-2024)
  • Table 226. South America Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 227. South America Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 228. South America Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 229. South America Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 230. South America Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 231. South America Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 232. Brazil Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 233. Brazil Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 234. Brazil Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 235. Brazil Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 236. Brazil Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 237. Brazil Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 238. Argentina Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 239. Argentina Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 240. Argentina Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 241. Argentina Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 242. Argentina Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 243. Argentina Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 244. Rest of South America Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 245. Rest of South America Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 246. Rest of South America Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 247. Rest of South America Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 248. Rest of South America Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 249. Rest of South America Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 250. Asia Pacific Autoimmune Treatment, by Country USD Million (2019-2024)
  • Table 251. Asia Pacific Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 252. Asia Pacific Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 253. Asia Pacific Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 254. Asia Pacific Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 255. Asia Pacific Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 256. Asia Pacific Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 257. China Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 258. China Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 259. China Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 260. China Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 261. China Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 262. China Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 263. Japan Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 264. Japan Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 265. Japan Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 266. Japan Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 267. Japan Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 268. Japan Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 269. India Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 270. India Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 271. India Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 272. India Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 273. India Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 274. India Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 275. South Korea Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 276. South Korea Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 277. South Korea Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 278. South Korea Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 279. South Korea Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 280. South Korea Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 281. Taiwan Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 282. Taiwan Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 283. Taiwan Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 284. Taiwan Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 285. Taiwan Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 286. Taiwan Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 287. Australia Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 288. Australia Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 289. Australia Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 290. Australia Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 291. Australia Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 292. Australia Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 293. Rest of Asia-Pacific Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 294. Rest of Asia-Pacific Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 295. Rest of Asia-Pacific Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 296. Rest of Asia-Pacific Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 297. Rest of Asia-Pacific Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 298. Rest of Asia-Pacific Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 299. Europe Autoimmune Treatment, by Country USD Million (2019-2024)
  • Table 300. Europe Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 301. Europe Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 302. Europe Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 303. Europe Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 304. Europe Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 305. Europe Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 306. Germany Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 307. Germany Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 308. Germany Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 309. Germany Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 310. Germany Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 311. Germany Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 312. France Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 313. France Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 314. France Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 315. France Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 316. France Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 317. France Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 318. Italy Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 319. Italy Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 320. Italy Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 321. Italy Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 322. Italy Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 323. Italy Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 324. United Kingdom Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 325. United Kingdom Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 326. United Kingdom Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 327. United Kingdom Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 328. United Kingdom Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 329. United Kingdom Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 330. Netherlands Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 331. Netherlands Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 332. Netherlands Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 333. Netherlands Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 334. Netherlands Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 335. Netherlands Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 336. Rest of Europe Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 337. Rest of Europe Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 338. Rest of Europe Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 339. Rest of Europe Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 340. Rest of Europe Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 341. Rest of Europe Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 342. MEA Autoimmune Treatment, by Country USD Million (2019-2024)
  • Table 343. MEA Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 344. MEA Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 345. MEA Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 346. MEA Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 347. MEA Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 348. MEA Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 349. Middle East Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 350. Middle East Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 351. Middle East Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 352. Middle East Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 353. Middle East Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 354. Middle East Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 355. Africa Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 356. Africa Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 357. Africa Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 358. Africa Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 359. Africa Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 360. Africa Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 361. North America Autoimmune Treatment, by Country USD Million (2019-2024)
  • Table 362. North America Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 363. North America Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 364. North America Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 365. North America Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 366. North America Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 367. North America Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 368. United States Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 369. United States Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 370. United States Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 371. United States Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 372. United States Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 373. United States Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 374. Canada Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 375. Canada Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 376. Canada Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 377. Canada Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 378. Canada Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 379. Canada Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 380. Mexico Autoimmune Treatment, by Type USD Million (2019-2024)
  • Table 381. Mexico Autoimmune Treatment, by Application USD Million (2019-2024)
  • Table 382. Mexico Autoimmune Treatment, by Disease Type USD Million (2019-2024)
  • Table 383. Mexico Autoimmune Treatment, by Indication USD Million (2019-2024)
  • Table 384. Mexico Autoimmune Treatment, by Sales Channel USD Million (2019-2024)
  • Table 385. Mexico Autoimmune Treatment, by Diagnosis USD Million (2019-2024)
  • Table 386. Autoimmune Treatment: by Type(USD/Units)
  • Table 387. Research Programs/Design for This Report
  • Table 388. Key Data Information from Secondary Sources
  • Table 389. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Autoimmune Treatment: by Type USD Million (2013-2018)
  • Figure 5. Global Autoimmune Treatment: by Application USD Million (2013-2018)
  • Figure 6. Global Autoimmune Treatment: by Disease Type USD Million (2013-2018)
  • Figure 7. Global Autoimmune Treatment: by Indication USD Million (2013-2018)
  • Figure 8. Global Autoimmune Treatment: by Sales Channel USD Million (2013-2018)
  • Figure 9. Global Autoimmune Treatment: by Diagnosis USD Million (2013-2018)
  • Figure 10. South America Autoimmune Treatment Share (%), by Country
  • Figure 11. Asia Pacific Autoimmune Treatment Share (%), by Country
  • Figure 12. Europe Autoimmune Treatment Share (%), by Country
  • Figure 13. MEA Autoimmune Treatment Share (%), by Country
  • Figure 14. North America Autoimmune Treatment Share (%), by Country
  • Figure 15. Global Autoimmune Treatment: by Type USD/Units (2013-2018)
  • Figure 16. Global Autoimmune Treatment share by Players 2018 (%)
  • Figure 17. Global Autoimmune Treatment share by Players (Top 3) 2018(%)
  • Figure 18. Global Autoimmune Treatment share by Players (Top 5) 2018(%)
  • Figure 19. BCG Matrix for key Companies
  • Figure 20. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 21. Abbott Laboratories (United States) Revenue: by Geography 2018
  • Figure 22. Glaxo Smithkline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Glaxo Smithkline Plc (United Kingdom) Revenue: by Geography 2018
  • Figure 24. Mitsubishi Tanabe Pharma Corp (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Mitsubishi Tanabe Pharma Corp (Japan) Revenue: by Geography 2018
  • Figure 26. Lupin (India) Revenue, Net Income and Gross profit
  • Figure 27. Lupin (India) Revenue: by Geography 2018
  • Figure 28. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 29. Johnson & Johnson (United States) Revenue: by Geography 2018
  • Figure 30. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer (United States) Revenue: by Geography 2018
  • Figure 32. Novartis (United States) Revenue, Net Income and Gross profit
  • Figure 33. Novartis (United States) Revenue: by Geography 2018
  • Figure 34. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Roche (Switzerland) Revenue: by Geography 2018
  • Figure 36. Eli Lilly & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Eli Lilly & Co. (United States) Revenue: by Geography 2018
  • Figure 38. Boehringer Ingelheim Gmbh (Germany) Revenue, Net Income and Gross profit
  • Figure 39. Boehringer Ingelheim Gmbh (Germany) Revenue: by Geography 2018
  • Figure 40. Global Autoimmune Treatment: by Type USD Million (2019-2024)
  • Figure 41. Global Autoimmune Treatment: by Application USD Million (2019-2024)
  • Figure 42. Global Autoimmune Treatment: by Disease Type USD Million (2019-2024)
  • Figure 43. Global Autoimmune Treatment: by Indication USD Million (2019-2024)
  • Figure 44. Global Autoimmune Treatment: by Sales Channel USD Million (2019-2024)
  • Figure 45. Global Autoimmune Treatment: by Diagnosis USD Million (2019-2024)
  • Figure 46. South America Autoimmune Treatment Share (%), by Country
  • Figure 47. Asia Pacific Autoimmune Treatment Share (%), by Country
  • Figure 48. Europe Autoimmune Treatment Share (%), by Country
  • Figure 49. MEA Autoimmune Treatment Share (%), by Country
  • Figure 50. North America Autoimmune Treatment Share (%), by Country
  • Figure 51. Global Autoimmune Treatment: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Abbott Laboratories (United States)
  • Glaxo Smithkline Plc (United Kingdom)
  • Mitsubishi Tanabe Pharma Corp (Japan)
  • Lupin (India)
  • Johnson & Johnson (United States)
  • Pfizer (United States)
  • Novartis (United States)
  • Roche (Switzerland)
  • Eli Lilly & Co. (United States)
  • Boehringer Ingelheim Gmbh (Germany)
Additional players considered in the study are as follows:
Bayer-Schering Pharmaceuticals (Germany) , Amgen (United States) , Genentech, Inc. (United States) , Bristol-Myers Squibb Co. (United States) , Biocryst Pharmaceuticals Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation